The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies

BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangement is a series of mutations of non-small cell lung cancer (NSCLC) patients. Since 2011, multiple ALK inhibitors (ALKis) have been developed and launched for targeted therapy. In this study, we sought to investigate different strategies of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Guangming, Zhao, Xinliang, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Wu, Di, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264051/
https://www.ncbi.nlm.nih.gov/pubmed/35813748
http://dx.doi.org/10.21037/jtd-22-622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264051/
https://www.ncbi.nlm.nih.gov/pubmed/35813748
http://dx.doi.org/10.21037/jtd-22-622

Ejemplares similares